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Objective: We developed a novel sustained drug-eluting device using tacrolimus-eluting biodegradable
nanofiber to prevent anastomotic stricture and evaluated the effects in a rat abdominal aortic anastomosis
model.
Methods: In vitro and in vivo tacrolimus release tests for tacrolimus-eluting biodegradable nanofiber were per-
formed to confirm its sustained release. To verify the prevention of anastomotic stricture, tacrolimus-eluting bio-
degradable nanofiber was placed around the end-to-end anastomosis of abdominal aorta in rats. Five rats were
allocated to the following 5 groups: (1) control without tacrolimus-eluting biodegradable nanofiber, (2) 5 mg
of nanofiber only (0 wt% of tacrolimus), (3) 5 mg of tacrolimus-eluting biodegradable nanofiber containing
0.04 wt% of tacrolimus, (4) 5 mg of tacrolimus-eluting biodegradable nanofiber containing 0.1 wt% of tacroli-
mus, and (5) 5 mg of tacrolimus-eluting biodegradable nanofiber containing 1.0 wt% of tacrolimus. Morphomet-
ric and histologic analyses including immunohistochemistry were performed in each of the groups 2 weeks after
the operation.
Results: The tacrolimus-eluting biodegradable nanofiber gradually released tacrolimus for at least 1 month in
vitro and in vivo. The ratio of intimal area was significantly reduced in the 1.0 wt% tacrolimus-eluting biode-
gradable nanofiber group compared with the other groups (0.26, 0.24, 0.25, 0.21, and 0.08 in control, 0 wt%,
0.04 wt%, 0.1 wt%, and 1.0 wt%, respectively, P< .05). The cells, which constitute intimal hyperplasia, were
positive for smooth muscle actin and SMemb, and factor VIII revealed that endothelial cells covered the surface
of the aortic lumen even in the 1.0 wt% tacrolimus-eluting biodegradable nanofiber group in immunohisto-
chemistry.
Conclusion: Tacrolimus-eluting biodegradable nanofiber reduced neointimal hyperplasia and preserved endo-
thelialization. This device may be useful in the prevention of anastomotic stricture.
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TAnastomotic stricture has remained the main reason for arte-
rial, venous, arteriovenous, and prosthetic graft failure.1-5 In
the area of coronary surgery, the surgical outcome of coro-
nary artery bypass grafting has remarkably improved, but al-
though arterial grafts have enhanced the long-term patency
rate, the long-term patency of saphenous vein grafts has
been limited.1,2 Approximately 20% of arterial grafts still
show evidence of occlusion or stenosis in the late period.3
The surgical outcome of an arteriovenous shunt has also
been limited, and its failure has caused severe morbidity.4
The prosthetic grafts used for peripheral bypass and hemodi-
alysis access have shown poor patency during the past few
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ture, whether the anastomosis is end to end or end to side, is
largely affected by the degree of neointimal hyperplasia,
which develops immediately after graft anastomosis.6 Pre-
venting anastomotic stricture is the key to long-term efficacy
of all types of vascular anastomosis and improves the
morbidity and prognosis of patients.
Percutaneous coronary intervention with drug-eluting
stents, which was introduced in 2003, has dramatically im-
proved restenosis rates compared with bare metal stents be-
cause the drug gradually prevents neointimal overgrowth
around the stent.7 We developed a novel sustained drug-re-
leasing device to prevent anastomotic stricture. Our new de-
vice is based on the prevention effect against neointimal
overgrowth by sustained release of the drug according to
the method of drug-eluting stents. The sustained-releasing
system is composed of biodegradable polymer, which dis-
solves continuously little by little, releasing the drug sponta-
neously. We chose tacrolimus for the drug to prevent
neointimal hyperplasia because it has been evaluated in pre-
vious studies as an agent to prevent neointimal hyperplasia
with respect to release kinetics, effective dosage, safety in
clinical practice, and benefit. However, it is difficult to deter-
mine what drug is the best to prevent neointimal hyper-
plasia.8-10 Gel, film, and other types of polymer have beenardiovascular Surgery c Volume 137, Number 3 703




TEBN ¼ tacrolimus-eluting biodegradable
nanofiber
VSMC ¼ vascular smooth muscle cell
reported for a drug-releasing system to prevent neointimal
hyperplasia.11-14 However, it is not clear which type of sys-
tem is preferable. These devices may not fit a complicated
anastomosis, such as an end-to-side anastomosis, because
of the lack of material flexibility.
We developed a nano-scale ‘‘cotton-wool’’ configuration
fiber by an electrospinningmethod tofit any type of anastomo-
sis. Tacrolimus, a field-proven antistricture agent, is mixed
with this biodegradable fiber for sustained release to create
tacrolimus-eluting biodegradable nanofiber (TEBN). This
type of cotton wool is well suited to perivascular application.
The aim of this study is to evaluate the effects of TEBN for
prevention of anastomotic stricture and to estimate the drug-
releasing level in a rat abdominal aortic anastomosis model.
MATERIALS AND METHODS
Animals
The animals were cared for in accordance with the ‘‘Guide for the Care
and Use of Laboratory Animals’’ published by the US National Institutes of
Health (Publication 85-23, National Academy Press, Washington, DC, re-
vised in 1996). All procedures involving animals were approved by the An-
imal Experiment Advisory Committee of the Nagoya University School of
Medicine. In this study, we used male Wistar rats 8 to 10 weeks old (weigh-
ing 300–350 g) that were purchased from the Chubu Kagaku Shizai Corpo-
ration (Nagoya, Japan).
Fabrication of Tacrolimus-Eluting Biodegradable
Nanofiber
We focused on tacrolimus as an antistricture agent because it has been
proved to be effective not only for immunosuppression but also for
treatment of scars or stent restenosis.10,15,16 Tacrolimus (Fermentel Ltd,
Jerusalem, Israel) was mixed with biodegradable polymer to achieve
sustained release. Our expectation was that tacrolimus would be released
when the biodegradable polymer was dissolved. We prepared poly(L-lac-
tide-co-glycolide), which consists of approximately 50% poly lactic acid
and 50% poly glycol acid, for the biodegradable polymer. To fabricate the
nano-scale ‘‘cotton-wool’’ configuration fiber, an electrospinning procedure
wasused.Thepolymer solutionwasaddedbyusinga1-mLsyringewitha right
angle-shapedmetal capillary attached to it. The circular orifice of the capillary
had an inner diameter of 1.2 mm. A flat counter electrode was located 35 cm
from the capillary tip. Pressure was applied to the solution in the syringe, grad-
ually forcing the piston tomaintain a steady flowof solution from the capillary
outlet. Theflow rate of thepolymer solutionwas0.3mL/min.The applied volt-
agewas in the range of 10 to 15 kV. The fibers released in the atmospherewere
electrostatically removed and trapped with a rod-shaped collector located 20
cm from the capillary tip. The nanofiber ranged from 100 to 800 nm in diam-
eter. The shape of theTEBNshows a ‘‘cottonwool’’-like formation (Figure 1).
This configuration is flexible and easy to handle for any type of vascular anas-
tomosis. The maximum tacrolimus content in the TEBN was 1.0 wt%.704 The Journal of Thoracic and Cardiovascular SuIn Vitro Release of Tacrolimus from Tacrolimus-
Eluting Biodegradable Nanofiber
The in vitro release of tacrolimus from the TEBNwas evaluated by mea-
surement of the remaining tacrolimus concentration in the TEBN, which
was incubated in phosphate-buffered saline (pH 7.4), in the following con-
ditions. Briefly, 10 mg containing 1.0 wt% of TEBNwas incubated in 1 mL
of phosphate-buffered saline at 37C, centrifuged, and lyophilized, and the
dry weight was measured. TEBN was dissolved in ethyl acetate, and the
polymer (poly[L-lactide-co-glycolide]) was removed by ethanol precipita-
tion. The extracts were dissolved in ethyl alcohol, and the concentration
of tacrolimus was measured with high-performance liquid chromatography.
The concentration of tacrolimus from TEBN was measured at each time
point (1, 4, 7, 14, 21, and 28 days, n ¼ 3 at each time point). Measurement
data were expressed as a percentage of the volume of tacrolimus originally
contained in the TEBN.
In Vivo Release of Tacrolimus from Tacrolimus-
Eluting Biodegradable Nanofiber and Side Effects
of Tacrolimus-Eluting Biodegradable Nanofiber
The in vivo release of tacrolimus from TEBN was also measured. Five
milligrams of TEBN containing 1.0 wt% of tacrolimus was subcutaneously
implanted into the backs of 30 Wistar rats. Five rats each were sacrificed 1,
3, 5, 7, 14, and 28 days after implantation. The remaining TEBN in the back
was collected, and the tacrolimus concentration in the TEBN was measured
in the same manner described above.
To verify the side effects of TEBN in the implanted rats, the blood con-
centration of tacrolimus (enzyme-linked immunosorbent assay; SRL, Inc,
Tokyo, Japan) was measured. This kit is useful for the therapeutic drug
monitoring of tacrolimus in the subtherapeutic and low therapeutic ranges.
Complete blood count, liver function (serum concentration of glutamic ox-
aloacetic transaminase, glutamic pyruvate transaminase, and gamma-gua-
nosine triphosphate), renal function (serum concentration of blood urea
nitrogen and creatinine), and pancreatic enzyme (amylase) tests were also
performed in these rats at each time point, and the results were compared
with those of sham-operated rats.
Operative Procedures and Treated Groups
The experiments were carried out on 25 Wistar rats. General anesthesia
was induced with etherization and maintained with 25 to 50 mg/kg of
FIGURE 1. Overall appearance of TEBN. TEBN looked like a ‘‘cotton
wool’’ formation.rgery c March 2009
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Tpentobarbital sodium (Kyoritsu Seiyaku Corp, Tokyo, Japan) and 0.01 mg/
kg of atropine sulfate (Mitsubishi Tanabe Pharma Corp, Osaka, Japan) in-
jected into the peritoneal cavity. An abdominal midline incision was
made to enter the peritoneal cavity, and the infrarenal abdominal aorta
was simply clamped and divided. The end-to-end anastomosis was made
by a continuous running suture with 9-0 silk (NESCO SUTURE, Alfresa
Pharma Corp, Tokyo, Japan). Neither anticoagulant nor antiplatelet agents
were administered throughout the procedure.
Rats were randomly divided into 5 groups (n¼ 5 in each group): (1) con-
trol without TEBN, (2) 5 mg of nanofiber (without tacrolimus), (3) 5 mg of
TEBN containing 0.04 wt% tacrolimus, (4) 5 mg of TEBN containing 0.1
wt% tacrolimus, and (5) 5 mg of TEBN containing 1.0 wt% tacrolimus.
Rats were sacrificed 2 weeks after operation and evaluated with the follow-
ing procedures.
Histologic Analysis and Ratio of Intima/Vessel wall
(IntimaþMedia) Area
For the histologic analysis, the anastomotic sites were resected beyond
the suture lines, fixed with 7.5% buffered formaldehyde (Sigma Aldrich Ja-
pan, Tokyo, Japan), and embedded in paraffin. Short axial consecutive 5-
mm serial sections were obtained just around the suture anastomosis. Three
individual and random sections from the anastomosis site were evaluated.
The sections were stained with hematoxylin-eosin (H&E) for morphometric
analysis. The area of the intima (including neointima) andmedia at the anas-
tomosis site was measured on the sections stained with H&E. To achieve
a reproducible result, the mean value of these areas (intima and media)
from 3 sections was adopted. To characterize neointimal hyperplasia, the ra-
tio of intimal area was calculated with the following formula: ratio of intimal
area ¼ intimal area/ (intimalþmedian area). This morphometric analysis
was performed using Image J for Mac OS X (Wane Rasband, National
Institutes of Health, Bethesda, Md).
Immunohistochemical Analysis for Neointimal
Hyperplasia and Endothelial Cells
Immunohistochemical staining was performed to identify the cell, which
comprised the intimal hyperplasia, and to evaluate reendothelialization at
the injured anastomotic site. To label mesenchymal cells (eg, smooth mus-
cle cell or myofibroblast) and endothelial cells, alpha-smooth muscle actin
antibody (1:3000) (Sigma-Aldrich Inc., St. Louis, Mo), SMemb (1:3000)
(Yamasa Co., Tokyo, Japan), and factor VIII antibody (ready-to-use for im-
munohistochemical staining) (NeoMarker, Fremont, Calif) were used as pri-
mary antibodies. Biotinylated secondary antibody (1:400) (anti-mouse
immunoglobulin-G; Vector Laboratories, Burlingame, Calif) was applied,
and avidin-biotin complex Vecstain ABC kit (Vector Laboratories, Burlin-
game, Calif) was used for visualization. Slides were developed in diamino-
benzidine solution and counterstained with H&E.
Statistical Analysis
Statistical analysis was performed using Excel for Mac with the add-in
software Statview for Mac (Version 5.0, SAS Institute Inc, Cary, N.C.).
Data were analyzed by 1-way analysis of variance, and multiple compari-
sons were made by the Scheffe procedure. Experimental results were
expressed as mean  standard deviation.
RESULTS
All animals survived to the end of our protocol, and no
sign of infection was detected.
Tacrolimus Release from Tacrolimus-Eluting
Biodegradable Nanofiber
In vitro release of tacrolimus from TEBN is shown in Fig-
ure 2. Approximately 30% of tacrolimus was released into
the solution from TEBN on the first day, but release persisted
thereafter, showing48% release at 2weeks and49% release at
4 weeks after incubating TEBN in phosphate-buffered saline.
In vivo release profiles of tacrolimus from TEBN are
shown in Figure 3. Early burst release was also observed
in vivo. Approximately 70% of the tacrolimus was released
from TEBN within the first day. After the initial burst phase
FIGURE 2. In vitro tacrolimus-releasing test with TEBN. Longitudinal
axis of this graph indicates the remaining percentage of tacrolimus in the
TEBN (%). The remaining tacrolimus curve seems to be logarithmic.
TEBN, Tacrolimus-eluting biodegradable nanofiber.
FIGURE 3. In vivo tacrolimus-releasing test with TEBN. Longitudinal
axis of this graph indicates remaining percentage of tacrolimus in the
TEBN (%). Tacrolimus was released at a fast initial burst phase during
the first few days followed by a slow sustained phase during the following
4 weeks. TEBN, Tacrolimus-eluting biodegradable nanofiber.The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 3 705
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Tduring the first few days, a slow release phase followed for 4
weeks. The in vivo experimental study confirmed the grad-
ual sustained release of tacrolimus from TEBN.
Ratio of Neointimal-Hyperplasia and
Immunohistochemical Staining
The ratio of intimal area (intimal area divided by the inti-
mal and medial area) in the control without TEBN, 5 mg of
nanofiber only, 5 mg of TEBN, and containing 0.04 wt%,
0.1 wt%, and 1.0 wt% tacrolimus were 0.26, 0.24, 0.25,
0.21, and 0.08, respectively (Figure 4). Only TEBN with
FIGURE 4. Ratio of intimal area. The neointimal hyperplasia is signifi-
cantly inhibited by 1.0 wt% TEBN. TEBN, Tacrolimus-eluting biodegrad-
able nanofiber.706 The Journal of Thoracic and Cardiovascular Su1.0 wt% of tacrolimus inhibited neointimal hyperplasia
significantly. Anastomotic sections stained with H&E are
shown in Figure 5. The cells constituting the intimal hyper-
plasia were alpha-smoothmuscle actin antibody and SMemb
positive in immunohistochemistry. Endothelial cells, which
were stained with factor VIII immunohistochemically, cov-
ered the surface of the aortic lumen even in the 1.0 wt%
TEBN group, in which neointimal hyperplasia was signifi-
cantly inhibited (Figure 6).
Consideration of Side Effects
There was no difference between the TEBN group and the
sham group in complete blood count, liver function test re-
sults, renal function test results, and pancreatic enzymes.
There was no blood concentration of tacrolimus in either
group. There was no anastomotic aneurysm or pseudoaneur-
ysm formation during the 2 weeks of the protocol.
DISCUSSION
The main finding of this study was that gradual sustained
release of tacrolimus from TEBN applied perivascularly
inhibited neointimal hyperplasia and preserved endotheliali-
zation after anastomotic stricture. Tacrolimus, a broad-
spectrum immunosuppressant drug discovered in 1984,
inhibits the progression of the cell cycle from the G1 to the
S phase of the mitotic cycle in the same manner as sirolimus.
It has been widely used for reducing the incidence andFIGURE 5. Histologic findings in the anastomotic site 2 weeks after operation. H&E staining of control group3200 (A) and340 (B), and TEBN containing
1.0 wt% tacrolimus3200 (C) and340 (D). Neointimal hyperplasia is significantly decreased in TEBN containing 1.0 wt% tacrolimus. A and C, Scale bar¼
100 mm. B and D, Scale bar ¼ 500 mm.rgery c March 2009
Mutsuga et al Evolving TechnologyFIGURE 6. Immunohistochemical staining in the anastomotic site 2 weeks after operation. Micrographs (original magnification, 3200) are representative
photographs. A–C, Control group. D–F, TEBN-containing 1.0 wt% tacrolimus group. A and D, Stained with alpha-smooth muscle actin antibody. Alpha-
smooth muscle actin antibody-positive cells are shown in neointimal hyperplasia and adventitia. B and E, Stained with SMemb. SMemb-positive cells are
shown in neointimal hyperplasia in control group. The longitudinal sections of (C) and (F) are stained with Factor VIII. Factor VIII-positive cells cover
the surface of the inner lumen. Scale bar ¼ 100 mm.E
Tseverity of allograft rejection after organ transplantation. It
has also been used to treat other inflammatory conditions,
such as atopic dermatitis. This agent has been shown to sup-
press T-cell activation and to inhibit the release of proinflam-
matory cytokines by binding to a cytosolic protein FKBP
(FK506 binding protein).15 The drug FKBP complex stably
associates with calcineurin and inhibits the serine/threonine
phosphatase activity of this Ca2þ-dependent enzyme, thus in-
hibiting calcineurin-dependent activation of lymphokine ex-
pression, apoptosis, and degranulation. Tacrolimus has been
demonstrated to inhibit several steps of the cascade leading to
neointimal proliferation.16 Inhibition of neointimal growth
causing vascular smooth muscle cell (VSMC) proliferation
was associated with reduced mitotic activity and diminished
alpha-actin-positive smooth muscle cells in the intimal layer.The Journal of Thoracic and CSirolimus and tacrolimus are macrolide antibiotics that
share potent immunosuppressive and anti-inflammatory
properties. Both bind to the immunophilin FKBP but trigger
different downstream mediators. Sirolimus inhibited VSMC
proliferation and migration in vitro and decreased stent
restenosis in experimental animals and human cases.17-20
External application of sirolimus by polymer sheets report-
edly resulted in anastomotic stricture inhibition of neointi-
mal hyperplasia.12 However, recent reports associated with
sirolimus-eluting stents revealed subacute stent thrombosis
and endothelial dysfunction, indicating insufficient reendo-
thelialization by sirolimus.21,22 Matter and colleagues23 re-
ported that tacrolimus was 100 times less potent than
sirolimus for inhibiting VSMC proliferation or migration
but exerted less antiproliferative effects on endothelial cellsardiovascular Surgery c Volume 137, Number 3 707
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Tcompared with sirolimus. They emphasized that sirolimus
inhibited endothelial cell proliferation and migration, and in-
duced late thrombosis and delayed endothelial recovery.
Fukuda and colleagues24 found that potent inhibitory effects
of sirolimus on vascular repair occur via stem and progenitor
cells in vitro, and that perivascular application of the drug
not only inhibited wire injury-induced neointima formation
in mice but also retarded reendothelization. Thus, we chose
tacrolimus (not sirolimus) in this study to avoid the above-
mentioned disadvantage of sirolimus.
Paclitaxel is also a powerful candidate as an antihyperpla-
sia agent, similar to sirolimus. Paclitaxel-eluting coronary
stents (Taxsus, Boston Scientific Corp, Natick, Mass) are
commercially available worldwide. We examined the effect
of paclitaxel in a pilot study with 1.0 wt% paclitaxel-eluting
biodegradable nanofiber. The effects of paclitaxel on vascu-
lar tissue were stronger than those of tacrolimus. There was
no endothelialization, and the number of cells was decreased
in the intimal and medial layers (data not shown). Therefore,
we did not apply paclitaxel in our experiments.
The preventative effect on neointimal hyperplasia from
the adventitial side has been reported.11,12 The adventitia
plays a great role in the maintenance of the integrity of the
inner layers of the arterial wall. Injury to the adventitia,
and more particularly to the vasa vasorum, can induce
intimal lesion formation despite an intact endothelium. The
adventitial myofibroblasts can migrate into the neointima
and synthesize several components of the extracellular ma-
trix.25-27 An advantage of perivascular delivery is that the
system is not in direct contact with blood and may reduce
the risk of thrombosis, even in association with the reactively
high dosage of the drug.
TEBN produced by electrospinningwas assessed as a pos-
sible drug delivery device for this type of application. The
shape of our new material, which consisted of nano-scale
‘‘cotton-wool’’ configuration fiber, has not been previously
reported. Compared with gel and film and other types of
polymer, our nano-scale ‘‘cotton-wool’’ configuration fiber
has a distinct advantage for local application on any type of
anastomotic suture site and for drug administration in a sus-
taining fashion. This nanofiber has been characterized with
respect to the morphology, proinflammatory response drug
distribution and release profiles, and ability of released
tacrolimus to inhibit the proliferation ofVSMC. Proliferation
of VSMC is highest in the first week after injury and can
continue 14 to 28 days depending on the severity of the in-
jury.26 We observed anastomotic stricture in our experimen-
tal (rat abdominal aortic anastomosis)model during 1, 2, 3, 4,
and 8 weeks (data not shown). The neointimal hyperplasia of
the anastomosis was the worst at 2 weeks during the 8-week
follow-up. Therefore, we decided to evaluate anastomotic
stricture at 2 weeks after operation. Meanwhile, according
to data of our in vivo release test, tacrolimus concentrations
released from TEBN revealed a logarithmic curve showing708 The Journal of Thoracic and Cardiovascular Sura fast initial burst phase during the first few days followed
by a slow sustained phase during the following 4 weeks.
This releasing pattern may provide an appropriate time pe-
riod for rat aortic vascular repair. If this is applied to a human
anastomotic stricture, it should be optimized for humans in
terms of the time of the stricture.
Study Limitations
This study was based on a rat aortic anastomosis model.
The vascular healing process of the rat may be different
from that of other animals and human beings. The tissue re-
action of the rat aortic anastomosis was worst 2 weeks after
operation and gradually regressed during 4 to 8 weeks.
Our anastomotic stricture model was established by
end-to-end aortic anastomosis, preventing us from correctly
evaluating other types of anastomosis (eg, end-to-side anas-
tomosis, which is usually performed in coronary artery by-
pass grafting). End-to-end anastomosis has morphologic
and hemodynamic differences from end-to-side arterial
anastomosis. There may be a histologic difference between
aortic anastomosis and peripheral arterial anastomosis.
Thus, we could not correctly assess the peripheral arterial
anastomotic stricture from our results.
Our method for measuring an intimal area was limited.
We carefully avoided cutting oblique sections, but it is not
altogether avoidable because of the short-axis section and
paraffin-embedded fixed sample cut into a 5-mm section.
However, we believe that over- and underestimation of
the intimal area can be prevented by taking the average of
3 sections.
The maximum tacrolimus content in the TEBN was 1.0
wt% because of technical limitations. We could not test
more than 1.0 wt% TEBN.
CONCLUSIONS
We developed a novel controlled drug-delivery device
called ‘‘TEBN.’’ This tacrolimus-releasing biodegradable
nanofiber ‘‘cotton-wool’’-like formation reduced neointimal
hyperplasia and preserved endothelialization in a rat model,
suggesting that it is a promising material for vascular anas-
tomosis.
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